



QUARTERLY REPORT
31 July 2024

AHAM World Series – **Biotechnology Fund**

MANAGER
AHAM Asset Management Berhad
199701014290 (429786-T)

TRUSTEE
TMF Trustees Malaysia Berhad
(200301008392 [610812-W])

Built On Trust

aham.com.my

AHAM WORLD SERIES – BIOTECHNOLOGY FUND

Quarterly Report and Financial Statements
As at 31 July 2024.

Contents	Page
QUARTERLY REPORT	2
STATEMENT OF COMPREHENSIVE INCOME	5
STATEMENT OF FINANCIAL POSITION	6
STATEMENT OF CHANGES IN ASSET	8

QUARTERLY REPORT

FUND INFORMATION

Fund Name	AHAM World Series – Biotechnology Fund
Fund Type	Growth
Fund Category	Feeder (wholesale)
Investment Objective	The Fund seeks to achieve capital appreciation over medium to long term period.
Benchmark	N/A
Distribution Policy	The Fund is not expected to make distribution. However, incidental distribution may be declared whenever is appropriate.

FUND PERFORMANCE DATA

USD Class

Category	As at 31 Jul 2024	As at 30 Apr 2024
Total NAV (USD'million)	0.625	-
NAV per Unit (USD)	0.5420	-
Unit in Circulation (million)	1.153	-

MYR Hedged-class

Category	As at 31 Jul 2024	As at 30 Apr 2024
Total NAV (RM'million)	13.777	-
NAV per Unit (RM)	0.5412	-
Unit in Circulation (million)	25.457	-

MYR Class

Category	As at 31 Jul 2024	As at 30 Apr 2024
Total NAV (SGD'million)	6.278	-
NAV per Unit (SGD)	0.5280	-
Unit in Circulation (million)	11.889	-

Fund Performance


USD Class

Table 1: Performance as at 31 July 2024

	Since Commencement (4/7/24 - 31/7/24)
USD	8.40%
MYR	5.60%
MYR Hedged	8.24%

Source of Benchmark: Bloomberg

Figure 1: Movement of the Fund versus the Benchmark



"This information is prepared by AHAM Asset Management Berhad for information purposes only. Past earnings or the fund's distribution record is not a guarantee or reflection of the fund's future earnings/future distributions. Investors are advised that unit prices, distributions payable and investment returns may go down as well as up."

Past performance is not necessarily indicative of future performance and that Unit prices and investment returns may go down, as well as up.

Asset Allocation

Fund's asset mix during the period under review:

	31 July 2024
	(%)
Unit Trust	96.73
Derivative	1.12
Cash & money market	2.15
Total	100.00

Income Distribution Breakdown

No distribution was declared by the Fund over the financial period under review.

Strategies Employed

The Biotechnology Fund aims to achieve capital appreciation over the medium to long term by investing in biotechnology and biotechnology-related companies. The fund allocates at least 85% of its assets to the Target Fund, which primarily invests in equities or equity-related instruments of biotechnology companies worldwide. The fund focuses on companies involved in developing small molecule or biologic drugs, research services, healthcare tools, and pharmaceuticals. The Biotechnology Fund invests in a diversified range of sectors within the biotechnology industry, including healthcare equipment, life sciences, and healthcare providers. The portfolio typically comprises a concentrated selection of 30 to 60 companies. The fund may use derivatives for hedging purposes, risk management, or to enhance returns, ensuring alignment with its investment goals.

Market Review

The biotechnology sector experienced mixed performance during the second quarter of 2024. The optimism that fueled a recovery in late 2023, particularly in small- and mid-cap biotech firms, was dampened as the anticipated interest rate cuts from the Federal Reserve (Fed) failed to materialize. As a result, the sector struggled against a backdrop of persistent rate hikes, which disproportionately affected growth-oriented biotech companies. Despite this broader market softness, several individual stocks within the sector made notable advances. Companies like Sarepta Therapeutics and Alnylam Pharmaceuticals made significant strides, achieving regulatory success and driving optimism around new therapies for Duchenne muscular dystrophy (DMD) and cardiovascular diseases, respectively.

Mergers and acquisitions (M&A), which surged toward the end of 2023, slowed slightly but remained a key feature in the biotech landscape. Valuations across the sector remained attractive, and several deals continued to occur at high premiums. Meanwhile, the biotech sector saw a surge in secondary stock offerings, with over \$28 billion raised in the first half of 2024. This influx of capital helped to solidify the balance sheets of many biotech companies, allowing them to continue research and development efforts, even amid market volatility. FDA approvals continued at a strong pace, with record numbers of therapies gaining approval. Innovation within the sector remained robust, as breakthrough treatments targeting major diseases like Alzheimer's, oncology, and rare diseases attracted investor interest despite broader market challenges.

Investment Outlook

Looking ahead, the biotechnology sector holds significant potential for continued growth, though challenges remain. We expect the market to remain sensitive to interest rate decisions by the Federal Reserve. A reduction in rates in the second half of the year could be a pivotal driver of performance, particularly for growth-oriented biotech companies that have been impacted by the tightening cycle. The outlook for M&A activity remains strong, especially as larger biopharma companies continue to seek acquisitions to replenish their product pipelines and address patent expirations.

Valuations in the biotech sector, particularly among small- and mid-cap companies, are still attractive following a three-year pullback. The combination of ongoing innovation, breakthrough treatments, and unmet medical needs in areas such as diabetes, obesity, cancer, and autoimmune diseases creates a compelling opportunity for long-term investors. We remain focused on identifying companies with newly launched products or promising late-stage pipelines that are poised for growth. Additionally, the continued pace of FDA approvals, coupled with open capital markets, should help support research and development in the sector. Overall, we maintain a cautiously optimistic outlook, with potential for strong performance in the latter half of 2024.

AHAM WORLD SERIES - BIOTECHNOLOGY FUND

UNAUDITED STATEMENT OF COMPREHENSIVE INCOME FOR THE FINANCIAL PERIOD ENDED 31 JULY 2024

Financial
period ended
31.7.2024
USD

INVESTMENT INCOME

Interest income from financial assets at amortised cost	531
Net gain on foreign currency exchange	2,758
Net gain on forward foreign currency contracts at fair value through profit or loss	55,793
Net gain on financial assets at fair value through profit or loss	84,649
	<hr/>
	143,731
	<hr/>

EXPENSES

Management fee	(4,735)
Trustee fee	(159)
	<hr/>
	(4,894)
	<hr/>

NET PROFIT BEFORE TAXATION

138,837

Taxation

-

INCREASE IN NET ASSETS ATTRIBUTABLE TO UNITHOLDERS

138,837

Increase in net asset attributable to unitholders
is made up of the following:

Realised amount	3,824
Unrealised amount	135,013
	<hr/>
	138,837
	<hr/>

AHAM WORLD SERIES - BIOTECHNOLOGY FUND

UNAUDITED STATEMENT OF FINANCIAL POSITION AS AT 31 JULY 2024

	<u>2024</u> USD
ASSETS	
Cash and cash equivalents	80,186
Amount due from Manager	
- creation of units	449,795
- management fee rebate receivable	2,570
Financial assets at fair value through profit or loss	4,832,079
Forward foreign currency contracts at fair value through profit or loss	55,793
TOTAL ASSETS	<u>5,420,423</u>
LIABILITIES	
Amount due to broker	420,000
Amount due to Manager	
- management fee	4,758
Amount due to Trustee	159
TOTAL LIABILITIES (EXCLUDING NET ASSET ATTRIBUTABLE TO UNITHOLDERS)	<u>424,917</u>
NET ASSET VALUE OF THE FUND	<u>4,995,506</u>
NET ASSETS ATTRIBUTABLE TO UNITHOLDERS	<u>4,995,506</u>

AHAM WORLD SERIES - BIOTECHNOLOGY FUND

UNAUDITED STATEMENT OF FINANCIAL POSITION AS AT 31 JULY 2024 (CONTINUED)

2024
USD

REPRESENTED BY:

FAIR VALUE OF OUTSTANDING UNITS

- MYR Class	1,368,101
- MYR Hedged-class	3,002,532
- USD Class	624,873
	<hr/>
	4,995,506
	<hr/> <hr/>

NUMBER OF UNITS IN CIRCULATION

- MYR Class	11,889,000
- MYR Hedged-class	25,457,000
- USD Class	1,153,000
	<hr/>
	38,499,000
	<hr/> <hr/>

NET ASSET VALUE PER UNIT (USD)

- MYR Class	0.1151
- MYR Hedged-class	0.1179
- USD Class	0.5420
	<hr/> <hr/>

NET ASSET VALUE PER UNIT IN RESPECTIVE CURRENCIES

- MYR Class	RM0.5280
- MYR Hedged-class	RM0.5412
- USD Class	USD0.5420
	<hr/> <hr/>

AHAM WORLD SERIES - BIOTECHNOLOGY FUND

UNAUDITED STATEMENT OF CHANGES IN NET ASSETS ATTRIBUTABLE TO UNITHOLDER FOR THE FINANCIAL PERIOD ENDED 31 JULY 2024

Financial
period ended
31.7.2024
USD

**NET ASSETS ATTRIBUTABLE TO UNITHOLDERS
AT THE DATE OF LAUNCH**

-

Movement due to units created and cancelled during the financial period

Creation of units arising from applications

4,856,669

- MYR Class
- MYR Hedged-class
- USD Class

1,309,419
2,938,280
608,970

Net increase in net assets attributable to unitholders during the financial period

138,837

- MYR Class
- MYR Hedged-class
- USD Class

58,682
64,252
15,903

**NET ASSETS ATTRIBUTABLE TO UNITHOLDERS
AT THE END OF THE FINANCIAL PERIOD**

4,995,506

AHAM Asset Management Berhad

Registration No: 199701014290 (429786-T)

Ground Floor, Menara Boustead, 69, Jalan Raja Chulan, 50200 Kuala Lumpur, Malaysia.

Toll Free Number: 1800 88 7080 T: +603 2116 6000

aham.com.my